Literature DB >> 28524748

An unwanted guest: Neisseria meningitidis - carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence.

Elena Gianchecchi1, Giulia Piccini1,2, Alessandro Torelli1,2, Rino Rappuoli3, Emanuele Montomoli1,4.   

Abstract

INTRODUCTION: Invasive Meningococcal Disease (IMD) represents a potentially life-threatening condition caused by Neisseria meningitidis. The disease is characterized by a case fatality rate of 5-10% whereas serious clinical sequelae can develop in survivors within 12-24 h from the first symptoms. However, IMD infection only occurs rarely, in fact, most of the interactions established between N. meningitidis and the host are harmless, and an estimated 10% of the population asymptomatically carries the bacterium in the nasopharynx. Meningococcal carriage represents a critical condition for IMD onset since it represents the first step for disease transmission. Furthermore, high levels of carriage can promote genetic recombination among different N. meningitidis strains potentially leading to the development of new pathogenic variants. Areas covered: The present review discusses N. meningitidis carriage, factors able to influence meningococcal carriage and disease and the effect of vaccinations on both conditions, with a particular focus on Italy. Expert commentary: Data regarding the effect of different meningococcal vaccines on N. meningitidis carriage are available, whereas further studies are needed to investigate the positive impact of the two recently licensed vaccines 4CMenB and rLP2086 on meningococcal carriage.

Entities:  

Keywords:  Invasive meningococcal disease; Italy; Neisseria meningitidis; meningococcal carriage; meningococcal vaccines; risk factors

Mesh:

Substances:

Year:  2017        PMID: 28524748     DOI: 10.1080/14787210.2017.1333422

Source DB:  PubMed          Journal:  Expert Rev Anti Infect Ther        ISSN: 1478-7210            Impact factor:   5.091


  5 in total

1.  Neisseria meningitidis serogroup B carriage by adolescents and young adults living in Milan, Italy: Prevalence of strains potentially covered by the presently available meningococcal B vaccines.

Authors:  Leonardo Terranova; Nicola Principi; Sonia Bianchini; Giada Di Pietro; Giulia Umbrello; Barbara Madini; Susanna Esposito
Journal:  Hum Vaccin Immunother       Date:  2018-05-09       Impact factor: 3.452

2.  Mass gatherings: a review of the scope for meningococcal vaccination in the Indian context.

Authors:  Anand P Dubey; Rashna Dass Hazarika; Veronique Abitbol; Shafi Kolhapure; Someya Agrawal
Journal:  Hum Vaccin Immunother       Date:  2021-02-19       Impact factor: 3.452

3.  [Genotypes of Neisseria meningitidis isolates in patients with meningococcal meningitis in Paraguay, 1996-2015Genótipos de Neisseria meningitidis isolados de pacientes com doença meningocócica no Paraguai, 1996-2015].

Authors:  María Eugenia León; Aníbal Kawabata; Minako Nagai; Liliana Rojas; Gustavo Chamorro
Journal:  Rev Panam Salud Publica       Date:  2019-02-13

4.  Postmarketing surveillance of adverse events following meningococcal B vaccination: data from Apulia Region, 2014-19.

Authors:  Pasquale Stefanizzi; Francesco Paolo Bianchi; Giuseppe Spinelli; Fabio Amoruso; Domenica Ancona; Paolo Stella; Silvio Tafuri
Journal:  Hum Vaccin Immunother       Date:  2021-08-26       Impact factor: 3.452

5.  Immunogenicity and safety of different schedules of the meningococcal ABCWY vaccine, with assessment of long-term antibody persistence and booster responses - results from two phase 2b randomized trials in adolescents.

Authors:  Timo Vesikari; Jerzy Brzostek; Anitta Ahonen; Marita Paassilta; Ewa Majda-Stanislawska; Leszek Szenborn; Miia Virta; Robert Clifford; Teresa Jackowska; Murray Kimmel; Ilaria Bindi; Pavitra Keshavan; Paola Pedotti; Daniela Toneatto
Journal:  Hum Vaccin Immunother       Date:  2021-09-28       Impact factor: 3.452

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.